p300/CBP has shown extraordinary potential target in cancer therapy. Herein we designed new compounds from the lead compound A-485 based on molecular dynamic simulations. A series of new spirocyclic chroman derivatives was prepared, characterized and proven to be a potential treatment of prostate cancer. The most potent compound B16 inhibited the proliferation of enzalutamide-resistant 22Rv1 cells with
作为参与细胞周期以及细胞生长,分化和发育的重要共激活因子,p300 / CBP在癌症治疗中显示出非凡的潜在靶标。在此,我们基于分子动力学模拟从
铅化合物A-485设计了新化合物。制备,表征并证明了一系列新的螺环苯并二氢
吡喃衍
生物是前列腺癌的潜在治疗方法。最有效的化合物B16抑制了耐enzalutamide的22Rv1细胞的增殖,IC 50值为96 nM。此外,在体内异种移植模型中,化合物B16 – P2表现出比A-485更好的总体药代动力学特征,并具有更好的肿瘤生长抑制作用。